Dytiatkovska Y. M., Nedohybchenko N. O.

THE QUALITY OF LIFE OF PATIENTS WITH FREQUENTLY RECURRING URTICARIA AND THE EFFECT OF DIFFERENT TREATMENT METHODS

---

Show/Download

About the author:

Dytiatkovska Y. M., Nedohybchenko N. O.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Chronic spontaneous urticaria is one of the most common allergic pathologies, and its impact on the quality of life of patients and the economic burden on the healthcare system determines the relevance of research to find an optimal management strategy. The work aimed to investigate the indicators of the quality of life of patients with severe chronic urticaria and to study the effect of omalizumab in comparison with desloratadine on the quality of life of patients to optimize treatment tactics. The prospective study included one hundred four patients with a clinical diagnosis of severe (according to the UAS7 scale) chronic spontaneous urticaria. In all patients, complaints were evaluated, anamnesis was studied, and a physical examination was performed. The SKINDEX-29 questionnaire was used to assess the quality of life. Patients were randomly divided into two groups: Group 1 (n=54) received one injection of omalizumab 150 mg every 21 days three times. Indicators of urticaria activity scale and quality of life were determined before treatment and ten days after each omalizumab injection. Group 2 (n=50) was prescribed desloratadine at 5 mg for the first four weeks and 20 mg for the next four weeks. Urticaria activity scale indicators and quality of life were determined before the start of treatment and five and nine weeks after the start of treatment. The patients included in the study are mostly of working age. The quality of life of the patients deteriorated in all areas. Against the background of treatment in Group 1, the severity of urticaria, the expressiveness of physical symptoms, the emotional sphere, functioning improved, and the overall assessment of the negative impact of the disease on the quality of life decreased significantly. In Group 2, the severity of urticaria and all indicators of the negative effect of the disease on quality of life also considerably reduced. However, at the end of the observation, the severity of urticaria and all domains of the negative impact of the disease on the quality of life remained pronounced in patients of this group. Treatment with omalizumab at a dosage of 150 mg once every 21 days in this patient category can be considered an effective therapy method that eliminates the symptoms of urticaria and significantly improves the quality of life.

Tags:

Bibliography:

1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2 LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-66.
2. Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-2016. DOI: 10.1111/all.13209.
3. Maurer M, Staubach P, Raap U, Richter-Huhn G, Baier-Ebert M, Chapman-Rothe N. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174(4):892-4.
4. Maurer M, Staubach P, Raap U, Richter-Huhn G, Bauer A, Ruëff F, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684-692. DOI: 10.1111/ cea.12900.
5. O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.
6. Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16(4):313-321. DOI: 10.1007/s40257-015-0134-8.
7. Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, et al. Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria. Pharmacoeconomics. 2016;34(8):815-27.
8. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75.
9. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.e4. DOI: 10.1016/j.jaci.2015.12.1342.
10. Finlay AY, Kaplan AP, Beck LA, Antonova EN, Balp M-M, Zazzali J, et al. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31(10):1715-1721. DOI: 10.1111/jdv.14384.
11. Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31(6):1056-1063. DOI: 10.1111/jdv.14075.
12. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014 Mar;150(3):288-90. DOI: 10.1001/jamadermatol. 2013.8705.
13. Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol. 2020 Aug;59(1):38-45. DOI: 10.1007/s12016-020-08794-6.
14. Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179(1):210-2.
15. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-87.
16. Chernyshov PV. Stvorennia ta mizhkulturna adaptatsiia ukrainskykh versii opytuvalnykiv SKINDEX-29, SKINDEX-16 indeksu nediiezdatnosti pry psoriazi ta podalsha validatsiia ukrainskoi versii dermatolohichnoho indeksu yakosti zhyttia. Likarska sprava. 2009;(1/2):95-8. [in Ukrainian].
17. Babienko VV, Mokiienko AV, Levkovska VIu. Biostatystyka. Odesa: «Pres-kur’yer»; 2022. 180 s. Dostupno: https://repo.odmu.edu.ua:443/ xmlui/ handle/123456789/11378. [in Ukrainian].
18. Pagano M, Gauvreau K, Mattie H. Principles of Biostatistics. CRC Press; 2022. 735 p.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 185-196 pages, index UDC 616.514-039.35-085.218-092.11

DOI:

10.29254/2077-4214-2023-2-169-185-196